Stress is an underlying cause of multiple diseases and according to the American Psychological Association (APA), 9 in 10 adults believe that stress contributes to the development of major illness.

Sentia is poised to be the world leader in the development of novel peptide therapeutics to manage and cure stress-related diseases by developing drugs called astressins that block the action of corticotropin releasing factor (CRF) and urocortins, the main mediators of the body’s response to stress. Astressins are designed to re-establish normal biological harmony with high efficacy and sustained effects.

See our science